B
Binghe Xu
Researcher at Peking Union Medical College
Publications - 284
Citations - 8216
Binghe Xu is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 34, co-authored 282 publications receiving 5863 citations.
Papers
More filters
Journal ArticleDOI
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Fatima Cardoso,Ana Costa,Elżbieta Senkus,Matti Aapro,Fabrice Andre,Carlos H. Barrios,Jonas Bergh,G. Bhattacharyya,Laura Biganzoli,Maria João Cardoso,Lisa A. Carey,D. Corneliussen-James,Giuseppe Curigliano,Véronique Diéras,N.S. El Saghir,Alex Eniu,Lesley Fallowfield,D. Fenech,Prudence A. Francis,Karen A. Gelmon,Alessandra Gennari,Nadia Harbeck,Clifford A. Hudis,Bella Kaufman,Ian E. Krop,Musa Mayer,H. Meijer,Shirley Mertz,S. Ohno,Olivia Pagani,E. Papadopoulos,Fedro A. Peccatori,Frédérique Penault-Llorca,Martine Piccart,Jean-Yves Pierga,Hope S. Rugo,Lillie D. Shockney,George W. Sledge,Sandra M Swain,Christoph Thomssen,Andrew Tutt,Daniel A. Vorobiof,Binghe Xu,Larry Norton,Eric P. Winer +44 more
TL;DR: This ESO-ESMO ABC 5 Clinical Practice Guideline provides key recommendations for managing advanced breast cancer patients, and provides updates on managing patients with all breast cancer subtypes, LABC, follow-up, palliative and supportive care.
Journal ArticleDOI
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
Eva Thomas,Henry L. Gomez,Rubi K. Li,Hyun Cheol Chung,Luis Fein,Valorie F. Chan,Jacek Jassem,Xavier Pivot,J. Klimovsky,Fernando Hurtado de Mendoza,Binghe Xu,Mario Campone,Guillermo Lerzo,Ronald Peck,Pralay Mukhopadhyay,Linda T. Vahdat,Henri Roché +16 more
TL;DR: Ixabepilone plus capecitabine demonstrates superior efficacy to cape citabine alone in patients with metastatic breast cancer pretreated or resistant to anthracyclines and resistant to taxanes.
Journal ArticleDOI
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Mark E. Robson,Nadine Tung,Pierfranco Conte,S-A. Im,Elżbieta Senkus,Binghe Xu,Norikazu Masuda,Suzette Delaloge,Wei Li,Andrew J. Armstrong,W. Wu,C. Goessl,Sarah Runswick,Susan M. Domchek +13 more
TL;DR: There was the possibility of meaningful OS benefit among patients who had not received chemotherapy for metastatic disease, and olaparib was generally well-tolerated, with no evidence of cumulative toxicity during extended exposure.
3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)
Fatima Cardoso,Ana Costa,Elżbieta Senkus,Matti Aapro,Fabrice Andre,Carlos H. Barrios,Jonas Bergh,G. Bhattacharyya,Laura Biganzoli,Maria João Cardoso,Lisa A. Carey,D. Corneliussen-James,Giuseppe Curigliano,Véronique Diéras,N.S. El Saghir,Alex Eniu,Lesley Fallowfield,D. Fenech,Prudence A. Francis,Karen A. Gelmon,Alessandra Gennari,Nadia Harbeck,Clifford A. Hudis,Bella Kaufman,Ian E. Krop,Musa Mayer,H. Meijer,Shirley Mertz,S. Ohno,Olivia Pagani,E. Papadopoulos,Fedro A. Peccatori,Frédérique Penault-Llorca,Martine Piccart,Jean-Yves Pierga,Hope S. Rugo,Lillie D. Shockney,George W. Sledge,Sandra M Swain,Christoph Thomssen,Andrew Tutt,Daniel A. Vorobiof,Binghe Xu,Larry Norton,Eric P. Winer +44 more
TL;DR: For Advanced Breast Cancer (ABC 3) F. Cardoso, A. Costa, E. Senkus, M. Mayer, H. Meijer, S. Shockney, G. Sledge, C. Tutt, D. Vorobiof, B. Xu, L. Norton & E. Winer European School of Oncology & Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal.
Journal ArticleDOI
Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.
Xichun Hu,Jian Zhang,Binghe Xu,Zefei Jiang,Joseph Ragaz,Zhongsheng Tong,Qingyuan Zhang,Xiaojia Wang,Ji-feng Feng,Dan-mei Pang,Minhao Fan,Jin Li,Biyun Wang,Zhonghua Wang,Qunling Zhang,Si Sun,Chun-mei Liao +16 more
TL;DR: The results indicate that apatinib dose of 500 mg rather than 750 mg is the recommended starting dose for the heavily pretreated mTNBC patients with measurable rate of partial response and PFS.